Bacteria Clinical Development In-Vivo Reagent 
Drug Discovery World
FEBRUARY 15, 2023
The first such research dates back to 1891, when William Coley attempted to inject heat-inactivated bacteria to treat osteosarcoma. To date, several preclinical IO models have been developed, with each type having their respective strengths and weaknesses. This continues to be the standard of care.
The Pharma Data
OCTOBER 14, 2020
Priothera will use the funds to progress the clinical development of mocravimod, a modulator of sphingosine 1 phosphate (S1P) receptors, to enhance the curative potential of allogeneic hematopoietic stem cell transplantation (HSCT) for treating AML. All jobs have been maintained and the workforce has grown from about 220 to 350.
Expert insights. Personalized for you.
52 
Let's personalize your content